Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions

HONG KONG, July 28, 2014 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that its new PicoWay® device has received CE Mark indication to treat tattoos of all types and colors and pigmented lesions on any skin type. PicoWay is a new and innovative dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes Syneron's proprietary PicoWay technology to deliver energy to the skin using pulses which are trillionths of a second, known as picosecond pulses. Syneron will begin a staged launch of the PicoWay device in the international market during the third quarter of 2014 and anticipates that it will receive U.S. Food and Drug Administration (FDA) clearance for PicoWay by the end of 2014.

PicoWay's high peak power and ultra-short pulse duration enable a unique mode of action which creates the strongest photo-mechanical impact to break up the tattoo ink or the pigmentation. This revolutionary PicoWay technology is integrated into a proven, reliable Candela® platform which ensures superior performance and low cost of ownership.

"Our investment in PicoWay's research and development demonstrate Syneron's commitment to develop technology that enables physicians to provide best-in-practice treatments for their patients," stated Amit Meridor, CEO of Syneron. "Since PicoWay has the shortest picosecond pulse duration and the highest peak power of any device on the market, we believe that fewer treatments will be needed and that the percentage clearance will be higher. We are pleased that Dr. Chan will present his positive results with PicoWay at IMCAS Asia, particularly because it will be a significant market for PicoWay due to the special value placed on clear skin in Asia."

Dr. Henry Chan, specialist in dermatology in Hong Kong, will present the interim results of a multi-center study focused on treating pigmented lesions with PicoWay at the IMCAS Asia Conference slated for August 1-3, 2014 in Hong Kong. His presentation is entitled "The Use of Picosecond Lasers on Asians".

Dr. Chan says "PicoWay's unique mode of picosecond action enables full flexibility to adjust the wavelength, fluence, spot size and rep rate, providing customizable treatments which ensure outstanding clinical results. The novel PicoWay technology enables our clinic to offer a new and exciting solution to remove pigmented lesions. The treatments have proven to be effective, safe and comfortable with a high satisfaction rate among our patients."

About Syneron
Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.  The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch.  

Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S.  The company markets, services and supports its products in 86 countries.  It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

For additional information, please visit http://www.syneron-candela.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, treatment results, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions, market acceptance of new products, and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical makes with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Additional information can be found at www.syneron-candela.com

Contacts:
Zack Kubow, The Ruth Group, [email protected], 646-536-7020
Hugo Goldman, Chief Financial Officer, Syneron, [email protected]
Syneron Medical Public Relations
 [email protected]

Logo - http://photos.prnewswire.com/prnh/20120528/535447

SOURCE Syneron Medical Ltd.